×
Home
About
Disclaimer
Privacy
JCS/T2D - We are advocates. We learn. We share. We inform.
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
200
500
All
Continuous Glucose Monitoring: A Game Changer for Type 2 Diabetes Management
Articles
Professor Juleen R. Zierath: Three Decades of Showing How Exercise Changes Metabolism
A More Human View of Glucose: How Hourly Visualizations Reduce Anxiety and Reveal Real Patterns
Wegovy Will Not Go OTC: What the Sources Actually Say
Bridging Data and Healthcare in the Nordics
How Well Do My CGM and BGM Readings Match?
Epigenetic Clues to Heart Risk in Type 2 Diabetes
Could a Gut Bacterium Help Transform Diabetes and Obesity Care?
Why mRNAs Are a Good Option for Vaccines
Why I Took Medical Courses to Strengthen My Data Skills
New Research Reveals the Hidden Complexity of Insulin Resistance
What the 2025 Diabetes Care Updates Mean for You
How an Hour-by-Hour View Transforms Time in Range Insights
Successfully Completed: Diabetes – A Global Challenge
Join the 5K@ADA Virtual Challenge to Promote Diabetes Awareness and Healthy Living
How Tirzepatide is Revolutionizing Type 2 Diabetes Prevention in Overweight and Obese Adults
Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
FDA Issues Alert on Compounded Semaglutide Dosing Errors
Join the 5K@EASD Virtual Challenge to Promote Diabetes Awareness and Healthy Living
Regulatory Hurdles for Awiqli: Approval in Canada and EU, Concerns in the US
Tirzepatide’s Efficacy in Treating Obstructive Sleep Apnea
News
March 2026
Zealand Pharma Reports Phase 2 Results for Petrelintide
February 2026
REDEFINE-4 Results: What They Mean for Patients
Novo Nordisk Renames Oral Semaglutide as Ozempic Pill Ahead of U.S. Launch
January 2026
Wegovy Oral Pill Launches in United States
December 2025
FDA Approves First Oral GLP-1 for Chronic Weight Management
Top Subjects
Type 2 Diabetes
Semaglutide
Obesity Treatment
Novo Nordisk
Wegovy
Tirzepatide
GLP-1
Eli Lilly
Ozempic
Clinical Trials
Obesity Care
Continuous Glucose Monitoring
Clinical Trial Results
Oral Semaglutide
EVOKE Trials
Alzheimer’s Disease
Oral GLP-1 Therapy
FDA Approval
Zepbound
Rybelsus
CagriSema
GLP-1 Therapy
GLP-1 Medicines
Drug Regulation
Medication Safety
Time in Range
Diabetes
Glucose Patterns
Diabetes Data Visualization
Emotional Impact of CGM
Contact Us
How many eyes does a typical person have?
Search
Search
You are here:
Home
JCS/T2D - A Diabetes Journey
